Lipella Pharmaceuticals Inc. (LIPO): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$1.19 | +$1.24 | n/a |
Métricas
- Precio de compra
- 0.03
- Ingresos (TTM)
- 390K
- Beneficio neto (TTM)
- -5.33M
- 1.57
- -2.26
- n/a
- 0
- P/B (TTM)
- 0.00
- P/S (TTM)
- 0.01
- Fecha de resultados
- n/a
- Precio de venta
- 0.04
- Volumen
- 160,086
- Volumen medio (20D)
- 21,177
- Abierto
- 0.06
- Anterior Cerrar
- 0.00
- Rango del día
- 0.03 - 0.06
- Rango de 52 semanas
- 0.00 - 0.64
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Lipella Pharmaceuticals Inc.
Ver perfil →Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.